Clinical Trials Browser

INDUSTRY × Interventional × tebentafusp × Clear all

NCT04262466 2026-03-06

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Phase 1/2 Active not recruiting

Other solid neoplasm

Select Advanced Solid Tumors

NCT05549297 2026-02-25

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Phase 3 Recruiting

Melanoma, Nevus, Blue

NCT05785754 2025-06-26

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Advanced or Metastatic Solid Tumors

NCT02535078 2024-07-24

Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma

Phase 1/2 Withdrawn

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

NCT02570308 2023-03-21

A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma

Phase 1/2 Completed

146 enrolled 26 charts

Uveal Melanoma, Melanoma